Table 2.

Geometric mean concentration of pneumococcal polysaccharide serotype-specific IgG, proportion with concentration above 0.35 μg/ml and proportion with concentration above 1.0 μg/ml for each group at baseline and for vaccinated groups at 1 and 6 months after immunization.

ST	Time-point	GMC (μg/ml)			Proportion >0.35 μg/ml			Proportion >1.0 μg/ml
		CHC	AHC	CP	CHC	AHC	CP	CHC	AHC	CP
1	0m	0.29	0.51	0.35	0.4	0.62	0.48	0.1	0.27	0.15
	1m	–	5.43	3.32	–	1.00a	0.98a	–	0.92a	0.81a
	6m	–	2.35	1.75	–	0.96a	0.94a	–	0.65a	0.67a
3	0m	0.30	0.25	0.18	0.4	0.38	0.27	0.16b	0.03	0.02
	1m	–	1.00	0.60	–	0.85a	0.65a	–	0.46a	0.29a
	6m	–	0.54	0.44	–	0.77a	0.58a	–	0.19	0.21a
4	0m	0.33	0.33	0.29	0.47	0.58	0.42	0.2	0.15	0.15
	1m	–	3.29	2.53	–	1.00a	0.92a	–	0.88a	0.75a
	6m	–	1.27	1.21	–	0.81a	0.83a	–	0.58a	0.52a
5	0m	0.56	0.66	0.58	0.77	0.85	0.77	0.27	0.35	0.31
	1m	–	3.22	1.76	–	1.00	0.88	–	0.81a	0.73a
	6m	–	1.74	1.23	–	0.96	0.85	–	0.73a	0.56a
6A	0m	1.03	1.21	0.82	0.83	0.96	0.79	0.57	0.54	0.48
	1m	–	10.54c,d	3.56	–	1.00	0.98a	–	1.00 a,e	0.81a
	6m	–	5.18c,d	2.20	–	1.00	0.92	–	0.96 a,e	0.71a
6B	0m	1.29f	1.08	0.68	0.97b	0.96e	0.73	0.63b	0.50	0.40
	1m	–	11.32c,d	3.31	–	1.00	0.94a	–	1.00 a,e	0.83a
	6m	–	5.12c,d	2.04	–	1.00	0.88a	–	0.96 a,e	0.75a
7F	0m	0.41g	0.91c	0.31	0.53	0.77e	0.46	0.27	0.50e	0.17
	1m	–	7.68c	3.01	–	1.00a	0.96a	–	0.96a	0.92a
	6m	–	3.45 c	1.66	–	0.96	0.94a	–	0.85a	0.65a
9V	0m	0.81f	0.67c	0.34	0.73	0.85e	0.58	0.4b	0.31e	0.08
	1m	–	4.58c	2.22	–	0.96	0.88a	–	0.92 a,e	0.73a
	6m	–	1.93	1.18	–	0.96	0.85a	–	0.77a	0.60a
14	0m	1.06	2.30c	0.73	0.77	0.85e	0.60	0.47	0.65	0.44
	1m	–	18.53 c	7.88	–	1.00	0.90a	–	1.00 a,e	0.79a
	6m	–	11.36	5.44	–	1.00	0.90a	–	1.00 a,e	0.81a
18C	0m	0.67	0.90c	0.35	0.73b	0.81e	0.50	0.37	0.50e	0.25
	1m	–	8.58c	2.51	–	0.96	0.85a	–	0.96 a,e	0.75a
	6m	–	3.93c	1.31	–	0.92	0.81a	–	0.85 a,e	0.60a
19A	0m	2.22	2.72	1.97	0.97	0.96	0.92	0.8	0.85	0.81
	1m	–	10.49c	7.14	–	1.00	0.98	–	1.00a	0.94a
	6m	–	5.80	4.46	–	1.00	0.98	–	0.92	0.92
19F	0m	1.10	1.43c	0.66	0.87	0.89	0.77	0.53	0.58	0.40
	1m	–	8.56	4.06	–	1.00	0.96a	–	0.96a	0.88a
	6m	–	4.19	2.49	–	1.00	0.94a	–	0.88a	0.75a
23F	0m	0.65f	0.62c	0.29	0.63b	0.69e	0.38	0.37b	0.35e	0.13
	1m	–	17.09c,d	2.12	–	1.00a	0.81a	–	1.00 a,e	0.69a
	6m	–	7.25c,d	1.17	–	1.00a	0.75a	–	0.92 a,e	0.56a

Chi-square and Fisher's exact tests were used to compare baseline proportions above a cut-off between groups. One-way analysis of variance (ANOVA) with Bonferroni correction was used to compare log-transformed antibody concentrations at baseline between groups. Chi-square was used to compare proportions above a cut-off between groups at each time- point after immunization. McNemar's test was used to detect changes in proportion from baseline within groups. Repeated-measures ANOVA and analysis of covariance were used to compare log-transformed antibody concentrations between and within group. Post-hoc analyses for simple effects were then performed as appropriate. 0m, baseline; 1m, 1 month after immunization; 6m, 6 months after immunization; AHC, adult healthy control; CHC, child healthy control; CP, child patient; ST, serotype.

^aProportion above cut-off significantly different before vs. after immunization (P < 0.05).

^bProportion above cut-off significantly different CHC vs. CP (P < 0.05).

^cGMC significantly different AHC vs. CP (P < 0.05).

^dGMC significantly different AHC vs. CP after adjusting for baseline (P < 0.05).

^eProportion above cut-off significantly different AHC vs. CP (P < 0.05).

^fGMC significantly different CHC vs. CP (P < 0.05).

^gGMC significantly different CHC vs. AHC (P < 0.05).